Physician profile
Cristy Sharp
NPI 1467475038
$10,561.41
in general payments reported to CMS, 2019-2025
37 companies · $875 in 2025
The $875 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,410 · 2022: $2,980 · 2023: $2,833 · 2024: $1,462 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,171.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,420.96 | 2021-2025 | |
| Novo Nordisk INC | $1,681.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $926.09 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $752.23 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $633.12 | 2021-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $633.03 | 2021-2024 | Trintellix |
| Glaxosmithkline, LLC. | $625.30 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.17 | 2021-2024 | Jardiance, Ofev |
| Pfizer INC. | $425.99 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $245.12 | 2021-2023 | Belsomra, Steglatro, Steglujan |
| Kowa Pharmaceuticals America, INC. | $213.00 | 2021-2023 | Seglentis, Livalo |
| Corium, LLC | $190.31 | 2022-2024 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $162.90 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $138.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $121.18 | 2022-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristy Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.